Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Ligand Pharmaceuticals Incorporated (LGND) had Revenue of $115.46M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$115.46M
Net Income	$117.27M
Cost of Goods Sold	$3.80M
Gross Profit	$111.66M
Operating Expenses	$60.53M
Operating Income	$54.93M
Non-Operating Income/Expense	$86.21M
Pre-Tax Income	$141.14M
Normalized Pre-Tax Income	$133.34M
Income after Taxes	$117.27M
Income from Continuous Operations	$117.27M
Consolidated Net Income/Loss	$117.27M
Normalized Income after Taxes	$108.16M
EBIT	$54.93M
EBITDA	$62.31M
Weighted-Average Shares Outstanding (Basic)	19.58M
Weighted-Average Shares Outstanding (Diluted)	20.63M
Earnings per Share (EPS) (Basic)	$5.99
Earnings per Share (EPS) (Diluted)	$5.68
Balance Sheet Financials
Current Assets	$753.92M
Property, Plant, and Equipment	$3.47M
Long-Term Assets	$722.85M
Total Assets	$1.48B
Current Liabilities	$30.54M
Long-Term Debt	$445.49M
Long-Term Liabilities	$496.06M
Total Liabilities	$526.60M
Common Equity	$950.17M
Tangible Shareholders Equity	$615.10M
Shareholders Equity	$950.17M
Common Shares Outstanding	19.66M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$3.44M
Cash Flow from Investing Activities	$-359.22M
Cash Flow from Financial Activities	$419.89M
Beginning Cash	$72.31M
End Cash	$139.38M
Increase/Decrease in Cash	$67.07M
Stock-Based Compensation	$32.58M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	24.69
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.32
Debt to Equity Ratio	0.47
Gross Margin	96.71%
Operating Margin	47.58%
EBIT Margin	47.58%
EBITDA Margin	--
Pre-Tax Profit Margin	122.24%
Profit Margin	101.57%
Free Cash Flow	$2.19M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.32
Receiveable Turnover	1.99
Days Sales in Receivables	45.28
Return on Equity	12.34%
Return on Tangible Equity	19.07%
Return on Assets	7.94%
Return on Investments	8.40%
Book Value Per Share	$48.34
Free Cash Flow per Share	$0.11
Operating Cash Flow per Share	$0.17

Data from Zacks Investment Research, Inc.